These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36467087)

  • 1. Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS).
    Ma P; Pan X; Liu R; Qu Y; Xie L; Xie J; Cao L; Chen Y
    Front Pharmacol; 2022; 13():1017889. PubMed ID: 36467087
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS).
    Xiong X; Zhang X; Li X; Huang T
    Expert Opin Drug Saf; 2024 Feb; ():1-6. PubMed ID: 38404234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
    Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
    Jiang A; Wei C; Zhu W; Wu F; Wu B
    Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
    Zhao D; Long X; Zhou J; Wang J
    Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-vascular endothelial growth factor monoclonal antibodies: a World Health Organization pharmacovigilance study.
    Yang JM; Jung SY; Kim MS; Lee SW; Yon DK; Shin JI; Lee JY
    Ophthalmology; 2024 Jul; ():. PubMed ID: 39004231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
    Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
    Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
    Li Z; Guo C; Liu X; Qiu Z; Zhang R
    Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
    [No Abstract]   [Full Text] [Related]  

  • 12. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
    Zhao D; Zhang W; Liu Y; Yan Z
    Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
    Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
    Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016.
    Ha D; Choi SR; Kwon Y; Park HH; Shin JY
    Medicine (Baltimore); 2019 Aug; 98(33):e16785. PubMed ID: 31415382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
    Gastaldon C; Raschi E; Kane JM; Barbui C; Schoretsanitis G
    Psychother Psychosom; 2021; 90(1):41-48. PubMed ID: 32854103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
    Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety evaluation of ceftazidime/avibactam based on FAERS database.
    Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
    Infection; 2024 Jun; ():. PubMed ID: 38842750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.